Literature DB >> 20970419

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.

Mo Shen1, Wei Chen, Kaiyuan Yu, Zhanguo Chen, Wu Zhou, Xiaomei Lin, Zhiliang Weng, Chengdi Li, Xiuling Wu, Zhihua Tao.   

Abstract

Prostate cancer gene 3 (PCA3) encodes a prostate-specific mRNA that has shown promise as a prostate cancer (PCa) diagnostic tool and is detectable in prostate cancer cells shedding into urine after digital rectal examination (DRE). In our earlier studies, a tissue test for PCA3 appeared to have greater specificity for PCa. There, we performed a clinical evaluation of PCA3 mRNA assay in urine sediments after DRE enriched with prostate cells in a Chinese population. PCA3 mRNA was detected by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (FQ-RT-PCR) in the urine sediments. PSA mRNA detected also by real-time FQ-RT-PCR was used to confirm the yield of prostate cells in the urine sediments beforehand and normalize PCA3 mRNA signals. The data were summarized in a receiver operating characteristic (ROC) curve to visualize the efficacy of ratio PCA3/PSA mRNA as a marker; sensitivity and specificity were calculated also. We also correlated the ratio PCA3/PSA mRNA to the biopsy results (including the presence or absence of malignancy and the Gleason score of the malignancy cases) and to the bone metastasis to evaluate its clinical value. The PCA3 mRNA expression (PCA3/PSA mRNA) in the PCa group was significantly higher than that in the BPH group. The AUC-ROC was 0.786 (95% CI: 0.683-0.889). When the cutoff value was set as 0.107, the sensitivity and specificity were 62.9% and 90.6%, respectively. The positive predictive value and negative predictive value of the PCA3 urine test was 78.6% and 81.7%, respectively. No significant correlation was found between urine PCA3 expression and Gleason score or bone metastasis. Results indicated the clinical usefulness of the PCA3/PSA mRNA of urine sediments after DRE as a molecular marker in the early diagnosis of prostate cancer, which appears to be highly specific for PCa. As a non-invasive and sample accessible assay, the PCA3/PSA mRNA may therefore be useful as an aid in the diagnosis of PCa. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970419     DOI: 10.1016/j.yexmp.2010.10.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  15 in total

1.  Long non-coding RNA LOC283070 mediates the transition of LNCaP cells into androgen-independent cells possibly via CAMK1D.

Authors:  Lina Wang; Yani Lin; Hui Meng; Chunyan Liu; Jing Xue; Qi Zhang; Chaoyang Li; Pengju Zhang; Fuai Cui; Weiwen Chen; Anli Jiang
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 2.  PCA3 in the detection and management of early prostate cancer.

Authors:  Xavier Filella; Laura Foj; Montserrat Milà; Josep M Augé; Rafael Molina; Wladimiro Jiménez
Journal:  Tumour Biol       Date:  2013-03-16

3.  Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Mozhde Askari; Amid Yazdani; Mohammad Yazdani; Mohammad Hossein Izadpanahi
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

Review 4.  Sarcosine as a potential prostate cancer biomarker--a review.

Authors:  Natalia Cernei; Zbynek Heger; Jaromir Gumulec; Ondrej Zitka; Michal Masarik; Petr Babula; Tomas Eckschlager; Marie Stiborova; Rene Kizek; Vojtech Adam
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

Review 5.  East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians.

Authors:  Tomomi Kimura
Journal:  Chin J Cancer       Date:  2011-11-15

6.  Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia.

Authors:  Jin Huang; Kathleen H Reilly; Hui-Zhen Zhang; Hai-Bo Wang
Journal:  BMC Urol       Date:  2015-12-01       Impact factor: 2.264

7.  Long non-coding RNA expression profile in human gastric cancer and its clinical significances.

Authors:  Haojun Song; Weiliang Sun; Guoliang Ye; Xiaoyun Ding; Zhong Liu; Sijie Zhang; Tian Xia; Bingxiu Xiao; Yang Xi; Junming Guo
Journal:  J Transl Med       Date:  2013-09-24       Impact factor: 5.531

8.  CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.

Authors:  Igor Tsaur; Anika Noack; Jasmina Makarevic; Elsie Oppermann; Ana Maria Waaga-Gasser; Martin Gasser; Hendrik Borgmann; Tanja Huesch; Kilian M Gust; Michael Reiter; David Schilling; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  Cancer Res Treat       Date:  2014-10-13       Impact factor: 4.679

9.  Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma.

Authors:  Sen-Lin Ma; Ai-Jun Li; Zhao-Yang Hu; Fu-Sheng Shang; Meng-Chao Wu
Journal:  Mol Med Rep       Date:  2015-10-13       Impact factor: 2.952

10.  Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers.

Authors:  Yingxue Wang; Zhihua Li; Shangyou Zheng; Yu Zhou; Lei Zhao; Huilin Ye; Xiaohui Zhao; Wenchao Gao; Zhiqiang Fu; Quanbo Zhou; Yimin Liu; Rufu Chen
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.